Patterns of serum CEA levels in different clinico-pathological variables of colorectal cancer

2020 ◽  
Vol 14 (2) ◽  
pp. 68-71
Author(s):  
Muhammad Hayat ◽  
Ghulam Haider ◽  
Shahid Hussain ◽  
Perwasha Kerio ◽  
Ravisha Bai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Tertiary Care ◽  
Elevated Serum ◽  
Response To Therapy ◽  
Care Hospital ◽  
Significant Difference ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea ◽  
Colorectal Cancer Patients

Background: Globally, colorectal malignancy is the 3rd most frequent cancer and the 2nd major cause of mortality. Serum carcinoembryonic antigen (CEA) is a simple tumor marker for the diagnosis, predicting response to therapy and survival and identifying the recurrence of colorectal cancer. Therefore, the aim was to evaluate the pattern of serum CEA levels in patients with colorectal cancer presenting at a tertiary care hospital in Karachi Patients and methods: It was a cross-sectional study conducted at the Department of Medical Oncology of Jinnah Postgraduate Medical Center, Karachi from January till August 2019. One ninety-nine patients of 12-80 years age and either gender diagnosed with colorectal cancer (biopsy-proven) were included. Data on demographics, clinical and pathological findings were recorded in the pre-designed proforma. The serum CEA levels in colorectal cancer patients were assessed using an ELISA kit. CEA levels higher than 5.0 ng/mL were deemed as elevated CEA levels in colorectal patients. Data were analyzed using SPSS version 23. Results: A total of 191 colorectal cancer patients were included. The mean age of the patients was 42.81±15.22 years. Most of the patients (61.3%) were male. Out of 191 colorectal cancer patients, 60 (31.4%) had CEA level 0-0.3 ng/ml, whereas 79 (41.4%) had elevated serum CEA level (>10 ng/ml). The CEA levels were stratified with respect to effect modifiers. The size of the tumor, TNM staging and localization and metastasis of cancer showed a statistically significant difference between levels of CEA (p<0.05). Conclusion: The raised CEA levels are associated with clinically progressive or presence of residual and recurrent disease. For patients with progressive tumors, particularly colorectal carcinoma, CEA assays are an important guide to assess the burden of the tumor, hence clinicians and surgeons ought to monitor antigen levels. It is recommended to enhance the clinical efficacy of the CEA levels.

scholarly journals Hubungan Nilai Carcinoembryonic Antigen dengan Derajat Diferensiasi pada Karsinoma Kolorektal di RSUP Prof. Dr. R. D. Kandou Manado

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
John Wesley ◽  
Toar Mambu ◽  
Heber Sapan ◽  
Winfried M. Sumanti
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Correlation Study ◽  
North Sulawesi ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea ◽  
Differentiation Stage ◽  
Colorectal Cancer Patients

Abstract: Colorectal cancer is a serious health problem in Indonesia as well as in North Sulawesi. Serum carcinoembryonic antigen (CEA) is a progmostic factor in patients with this disease. This study was aimed to obtain the correlation between the histopathological differentiation stage and serum CEA level in colorectal cancer patients at Prof. Dr. R. D. Kandou Hospital Manado. This was an analytical correlation study. Subjects were colorectal cancer patients who had preoperative serum CEA level and histopathological differentiation stage results. Data were analyzed with Anova test (variant analysis) and Spearman Rho test. The results showed that there were 58 colorectal cancer patients enrolled in this study. The patients’ data were obtained from the Digestive Surgery clinic and nursery room of Prof. Dr. R. D. Kandou Hospital Manado. Of the 58 patients, 37 (63.79%) had moderate differentiated colorectal cancer. Related to serum CEA level, 23 patients (39.65%) had moderate differentiated colorectal cancer with serum CEA level 20-100 ng/ml. The Spearman Rho test showed that there was a positive correlation between serum CEA level and histopathoplogical differentiation stage of cancer (r = 0.877 and P = 0.001). Conclusion: There was a significant correlation between serum CEA level and histopathological differentiation stage of colorectal cancer. The better the differentiation stage, the higher the serum CEA level.Keywords: carcinoembryonic antigen, colorectal cancer, differentiation stageAbstrak: Karsinoma kolorektal (KKR) telah menjadi masalah kesehatan yang serius di Indonesia dan Sulawesi Utara pada khususnya. Kadar carcinoembryonic antigen (CEA) merupakan salah satu faktor prognostik pada penderita KKR. Penelitian ini bertujuan untuk mengetahui hubungan antara derajat diferensiasi histopatologik dengan kadar CEA dalam serum pada pasien KKR di RSUP Prof. Dr. R. D. Kandou Manado. Jenis penelitian ini ialah analitik korelatif. Subyek penelitian ialah 58 pasien KKR yang mempunyai hasil pemeriksaan kadar CEA serum preoperasi dan pemeriksaan derajat diferensiasi histopatologik. Analisis statistik menggunakan uji Anova (analisis variansi) dan korelasi Spearman Rho. Data pasien diambil dari pasien yang datang dan kontrol di Poliklinik Bedah Digestif serta dari ruang perawatan Bedah Digestif RSUP Prof. Dr. R. D. Kandou Manado. Hasil penelitian memperlihatkan derajat diferensiasi tumor kolorektal terbanyak ialah diferensiasi sedang/moderate differentiated yaitu 37 pasien (63,79%). Bila dihubungkan dengan nilai CEA serum, yang terbanyak ditemukan ialah jenis diferensiasi sedang pada pasien dengan kadar CEA serum 20-100 ng/ml sebanyak 23 orang (39,65%). Uji Spearman Rho memperlihatkan bahwa kadar CEA berkorelasi positif dengan derajat diferensiasi KKR (r = 0,877 dan P = 0,0001). Simpulan: Terdapat korelasi bermakna antara kadar CEA serum dan derajat diferensiasi kanker kolorektal. Derajat diferensiasi KKR yang baik memiliki kadar CEA yang tinggi.Kata kunci: carcinoembryonic antigen, karsinoma kolorektal, derajat differensiasi

scholarly journals Interhospital referral of colorectal cancer patients: a Dutch population-based study

2021 ◽  
Author(s):  
A. K. Warps ◽  
◽  
M. P. M. de Neree tot Babberich ◽  
E. Dekker ◽  
M. W. J. M. Wouters ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Waiting Time ◽  
Secondary Care ◽  
Advanced Disease ◽  
Waiting Times ◽  
Tertiary Care ◽  
Disease Stage ◽  
Colorectal Cancer Patients ◽  
Tertiary Care Hospitals

Abstract Purpose Interhospital referral is a consequence of centralization of complex oncological care but might negatively impact waiting time, a quality indicator in the Netherlands. This study aims to evaluate characteristics and waiting times of patients with primary colorectal cancer who are referred between hospitals. Methods Data were extracted from the Dutch ColoRectal Audit (2015-2019). Waiting time between first tumor-positive biopsy until first treatment was compared between subgroups stratified for referral status, disease stage, and type of hospital. Results In total, 46,561 patients were included. Patients treated for colon or rectal cancer in secondary care hospitals were referred in 12.2% and 14.7%, respectively. In tertiary care hospitals, corresponding referral rates were 43.8% and 66.4%. Referred patients in tertiary care hospitals were younger, but had a more advanced disease stage, and underwent more often multivisceral resection and simultaneous metastasectomy than non-referred patients in secondary care hospitals (p<0.001). Referred patients were more often treated within national quality standards for waiting time compared to non-referred patients (p<0.001). For referred patients, longer waiting times prior to MDT were observed compared to non-referred patients within each hospital type, although most time was spent post-MDT. Conclusion A large proportion of colorectal cancer patients that are treated in tertiary care hospitals are referred from another hospital but mostly treated within standards for waiting time. These patients are younger but often have a more advanced disease. This suggests that these patients are willing to travel more but also reflects successful centralization of complex oncological patients in the Netherlands.

Short term outcome for colorectal cancer patients undergoing surgery in Tertiary care center in Eastern India

2021 ◽  
Vol 47 (2) ◽  
pp. e50-e51
Author(s):  
Abhitesh Singh ◽  
Anshul Jain ◽  
Dillip Muduly ◽  
Mahesh Sultania ◽  
Jyoti Ranjan Swain ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Eastern India ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome ◽  
Colorectal Cancer Patients

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

2011 ◽  
Vol 4 ◽  
pp. CGM.S7113 ◽  
Author(s):  
Ozgur Kemik ◽  
Ahu Sarbay Kemik ◽  
Aziz Sümer ◽  
Sevim Purisa ◽  
A. Cumhur Dulger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Stage Ii ◽  
Vascular Endothelial ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients

2007 ◽  
Vol 3 (6) ◽  
pp. 325-333 ◽  
Author(s):  
Francisco J. Gonzalez ◽  
Luis Vicioso ◽  
Martina Alvarez ◽  
Isabel Sevilla ◽  
Eduardo Marques ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Primary Colorectal Cancer ◽  
Vegf Expression ◽  
Colorectal Cancer Patients

5-fluorouracil (5FU) pharmacokinetic and hormonal status in female colorectal cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13576-13576
Author(s):  
A. Bononi ◽  
M. Gusella ◽  
G. Crepaldi ◽  
R. Padrini ◽  
E. Ferrazzi
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Plasma Levels ◽  
Elderly Women ◽  
Performance Status ◽  
Area Under The Curve ◽  
Pharmacokinetic Parameters ◽  
Hormonal Status ◽  
Significant Difference ◽  
Colorectal Cancer Patients

13576 Background: It is well known that females present a significantly reduced clearance of 5FU compared to males treated with the same doses.We tested the hypothesis that it may depend on the hormonal status, so that pre-menopausal women would have different 5FU pharmacokinetics compared with both postmenopausal women and elderly women. Methods: 48 colorectal cancer patients were prospectively studied: all of them were on adjuvant treatment based on 5FU repeated boluses. On the second day of the first cycle peripheral blood was drawn after drug administration. Plasma level were detected by HPLC analysis and pharmacokinetic parameters were calculated trough a one phase exponential decay model. Results: All patients had 100–90 Karnosky Performance status score. 12 were in pre-menopausal phase (age range : 40–55 years); among the others we distinguished a younger 19 people group (age lower than 70 years old) and an elderly 17 patient group (age equal or higher than 70 years old). They received a 5FU mean dose of 406 ± 15 mg/mq, not significantly different among the three groups. After intravenous bolus injection a high interindividual variability of 5-FU pharmacokinetics was detected: AUC0-∞ (area under the curve of drug plasma levels versus time) ranged between 368 and 1236 mg × min/L and the highest values (>1000) were found in two elderly patients, considered fit; anyway there was no significant difference among AUC of the three groups. 5FU total clearance ranged between 0.53 and 1.9 L/min and means were 1.07 ± 0.3, 1.02 ± 0.3 and 0.98 ± 0.3 L/min in pre-menopausal, postmenopausal and elderly women respectively; again 5FU clearance/ BSA (body surface area), half live elimination times and peak concentration plasma levels were not significantly different among the three groups. Conclusions: It seems that sexual hormonal status do not influence 5FU total body elimination capability, and that pharmacokinetic differences between genders should be related to other factors,as for example Body Composition. Funded by AIRC-Veneto No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document